Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gataparsen + Docetaxel in Advanced NSCLC
NCT01107444Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Primary completion
- Dec 2011
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of gataparsen in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Tumor Size to the End of Cycle 2. Started May 2010; status: completed.
02
Drugs
gataparsen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01107444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107444.